杭州糖吉医疗科技股份有限公司HANGZHOU TANGJI MEDICAL TECHNOLOGY CO., LTD.
GBS公立医院终端定价及医保集采情况
We have established a terminal price for the GBS procedure in public hospitals, generally ranging from RMB36,600 to RMB39,100 for a complete set comprising one delivery system and one retrieval system.
Business · 第 199 页
As of the Latest Practicable Date, our GBS is included in the provincial-level medical insurance reimbursement lists in 28 of the 30 provinces and municipalities where we have established commercial coverage, including Sichuan, Shandong, Hebei, Henan, Shanghai, Guangdong and Jiangsu.
Business · 第 199 页
As our GBS is a NMPA Class III Innovative Medical Device, as of the Latest Practicable Date, it was not subject to national or regional volume-based procurement (VBP) policies and programs.
Under the Vaccine Administration Law, Class II vaccine companies are required to follow reasonable pricing principles.
Business · 第 186 页
As Class II vaccines are ultimately paid by vaccinees, our pricing for such vaccines is primarily market-driven.
Business · 第 186 页
As a result, we have faced substantial challenges in securing orders at the district- and county-level CDCs where final procurement decisions are made; and (iii) the overall market demand for pediatric vaccines has experienced a downward trend in recent years, primarily due to the declining young population in China.
For instance, during the Track Record Period, we entered into several high-volume government procurement contracts at prices significantly lower than those in other contracts as we considered these large-volume orders strategically advantageous for enhancing our competitive position and brand recognition, which were in line with the industry practice and had a material impact on our revenue and gross profit margin.
Financial Information · 第 178 页
We participate in provincial-level centralized bidding processes and determine our bid prices independently and in a reasonable manner prior to submission.
For our quadrivalent subunit influenza vaccine, we set a uniform bidding price of RMB319 per dose across different provinces in China.
Business · 第 313 页
We set the price for our quadrivalent subunit influenza vaccine primarily considering existing influenza vaccine prices both domestically and internationally, along with an evaluation of our manufacturing costs.
BMP bone repair materials are among such products listed in Clause 5 and therefore, are subject to the Price Regulation to be imposed by relevant local regulatory authorities.
Summary · 第 24 页
As advised by CIC, there is a possibility that the expected price decrease for rhBMP-2 products following the implementation of the Price Regulation could range from 10% to 25%, based on three instances of similar price regulation policies enacted by certain local authorities.
Summary · 第 24 页
To increase the commercial potential of Guyoudao and mitigate the negative impact of price restrictions on our financial performance, we have taken measures including (i) strengthening the sales and marketing efforts of Guyoudao and further increasing its sales volume, (ii) continuing to develop next-generation of rhBMP-2 products to sustain and strengthen our competitive edge, and (iii) actively tracking relevant policy development.